Sampo Bank Ratings Raised To 'AA-' On Approval Of Danske Bank Acquisition Feb 07

  • ID: 2024157
  • February 2007
  • Standard & Poors
1 of 3


  • Danske Bank A/S
  • Danske Bank PLC
  • MORE

STOCKHOLM (Standard & Poor's) Feb. 7, 2007--Standard & Poor's Ratings Services said today that it had raised its long-term counterparty credit rating on Finland-based Sampo Bank PLC (Sampo Bank) to 'AA-' from 'A' and its short-term counterparty credit rating to 'A-1+' from 'A-1'. The ratings were removed from CreditWatch, where they were placed with positive implications on Nov. 9, 2006. The rating action follows regulatory approval of the acquisition of Sampo Bank by Denmark-based Danske Bank A/S (Danske Bank, AA-/Stable/A-1+). The rating action reflects Standard & Poor's view that Sampo Bank is a core subsidiary of Danske Bank. As such, the ratings on Sampo Bank are equalized with the ratings of its parent and the outlook aligned with that on...

Companies mentioned in this report are:
- Danske Bank PLC
- Danske Bank A/S

Action: Removed From CreditWatch
Action: Upgraded

Standard and Poors RatingsXpress Credit Research provides in-depth coverage of international corporates, financial institutions, insurance companies, utilities, sovereigns and structured finance programs. RatingsXpress Credit Research lets users determine the credit rating of holdings and identify key factors underlying an issuer's creditworthiness, distinguishes the different risk exposures for new and existing deals, and provides an understanding of how their analysts interpret key regulatory, political and environmental events and their economic impact.

Research type: News
This product is a is a brief one-page announcement of no more than 500 words with a quote from the analyst. It is media and investor focused with no accompanying commentary article.

Note: Product cover images may vary from those shown
2 of 3

- Danske Bank PLC
- Danske Bank A/S

Note: Product cover images may vary from those shown
3 of 3
Note: Product cover images may vary from those shown




Our Clients

  • Fluidigm Corporation
  • Apple, Inc.
  • CEVA Santé Animale
  • Abbott Laboratories Ltd.
  • Merck Group
  • Allergan Inc.
  • Pfizer Inc.